AEterna Zentaris (TSX:AEZS) Receivables Turnover : 0.39 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. AEterna Zentaris's Revenue for the three months ended in Dec. 2023 was C$0.16 Mil. AEterna Zentaris's average Accounts Receivable for the three months ended in Dec. 2023 was C$0.41 Mil. Hence, AEterna Zentaris's Receivables Turnover for the three months ended in Dec. 2023 was 0.39.

AEterna Zentaris Receivables Turnover Historical Data

The historical data trend for AEterna Zentaris's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Receivables Turnover Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

3.00

5.19

5.09

9.18

18.95

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Receivables Turnover	Get a 7-Day Free Trial															6.38	4.45	5.92	0.01	0.39

Competitive Comparison of AEterna Zentaris's Receivables Turnover

For the Biotechnology subindustry, AEterna Zentaris's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Receivables Turnover falls into.

AEterna Zentaris Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

AEterna Zentaris's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	6.035	/ (	(0.547	+	0.09)	/	2 )
=	6.035	/	0.3185
=	18.95

AEterna Zentaris's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Sep. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	0.162	/ (	(0.739	+	0.09)	/	2 )
=	0.162	/	0.4145
=	0.39

AEterna Zentaris (TSX:AEZS) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

AEterna Zentaris Receivables Turnover Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.